Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria.

Blood
Jean-Marc BlouinE Richard

Abstract

Congenital erythropoietic porphyria (CEP) is an inborn error of heme synthesis resulting from uroporphyrinogen III synthase (UROS) deficiency and the accumulation of nonphysiological porphyrin isomer I metabolites. Clinical features are heterogeneous among patients with CEP but usually combine skin photosensitivity and chronic hemolytic anemia, the severity of which is related to porphyrin overload. Therapeutic options include symptomatic strategies only and are unsatisfactory. One promising approach to treating CEP is to reduce the erythroid production of porphyrins through substrate reduction therapy by inhibiting 5-aminolevulinate synthase 2 (ALAS2), the first and rate-limiting enzyme in the heme biosynthetic pathway. We efficiently reduced porphyrin accumulation after RNA interference-mediated downregulation of ALAS2 in human erythroid cellular models of CEP disease. Taking advantage of the physiological iron-dependent posttranscriptional regulation of ALAS2, we evaluated whether iron chelation with deferiprone could decrease ALAS2 expression and subsequent porphyrin production in vitro and in vivo in a CEP murine model. Treatment with deferiprone of UROS-deficient erythroid cell lines and peripheral blood CD34+-derived ery...Continue Reading

References

Dec 3, 1999·The International Journal of Biochemistry & Cell Biology·T J SadlonB K May
May 1, 2002·Nature Biotechnology·Thi My Anh Neildez-NguyenLuc Douay
Nov 30, 2005·Genomics·C GedH de Verneuil
Jun 10, 2008·Current Gene Therapy·Emmanuel RichardHubert de Verneuil
Sep 11, 2008·Human Molecular Genetics·Gaelle Douillard-GuillouxEmmanuel Richard
Jul 19, 2012·The British Journal of Dermatology·R P KatugampolaM N Badminton
Jul 24, 2012·The British Journal of Dermatology·R P KatugampolaA V Anstey
Oct 23, 2013·Proceedings of the National Academy of Sciences of the United States of America·Jean-Marc BlouinEmmanuel Richard
Feb 8, 2014·Current Opinion in Hematology·Sujit Sheth
Mar 13, 2016·British Journal of Haematology·Elena Di PierroFrancesca Granata
Aug 31, 2017·The New England Journal of Medicine·D Montgomery BissellHerbert L Bonkovsky
Mar 4, 2018·Journal of Genetics and Genomics = Yi Chuan Xue Bao·Michael J Gambello, Hong Li
Sep 21, 2018·Science Translational Medicine·Pedro UrquizaOscar Millet
Nov 30, 2018·The New England Journal of Medicine·Robert C Hider, A Victor Hoffbrand
Jan 28, 2019·Molecular Genetics and Metabolism·Angelika L Erwin, Robert J Desnick
Feb 7, 2019·The New England Journal of Medicine·Eliane SardhKarl E Anderson
Aug 10, 2019·Molecular Genetics and Metabolism·Charles J ParkerJohn D Phillips
Oct 12, 2019·Biochemical and Biophysical Research Communications·Thibaud LefebvreCécile Ged
Jan 29, 2020·American Journal of Hematology·Paul J SchmidtMark D Fleming

❮ Previous
Next ❯

Citations

Nov 20, 2020·Blood·Janis L Abkowitz
Mar 5, 2021·Molecular Genetics and Metabolism Reports·Jean-Marc BlouinEmmanuel Richard
May 7, 2021·Scientific Reports·Juliana Bragazzi CunhaM Bishr Omary
Jun 30, 2021·Der Internist·Ulrich StölzelIlja Kubisch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.